Draft
There is a new drug developed by a therapeutical company that targets sickle cell disease. This new drug, that will be sold under the name of Oxybryta, will cost $125,000 a year. Oxybryta will be the first drug to specifically target the root cause of the sickling cell. Sickle cell disease originated in Africa that prematurely kills 50-90% of the millions born with this disease. Hemoglobin in people with this disease aggregate to from rock hard rods that give them the sickle shape. These sickle cells then block blood vessels and triggers intense pain. The sickle cells are also prone to shattering. These problems lead to kidney failure and often early death.
Recent comments